Evidence map›Paper›PMID 40660704›Full record

ArticleBiotechnology progress

PEGylation of polymerized albumin retains colloid osmotic pressure: Towards an enhanced potential plasma substitute.

Amna Abdalbaqi, Ahmad Yahya, Krianthan Govender, Carlos Muñoz, Gala Sanchez Van Moer, Daniela Lucas, Pedro Cabrales, Andre F Palmer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amna AbdalbaqiWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.ORCID 0000-0002-2701-4547
Ahmad YahyaWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.
Krianthan GovenderDepartment of Bioengineering, University of California San Diego, La Jolla, California, USA.
Carlos MuñozDepartment of Bioengineering, University of California San Diego, La Jolla, California, USA.
Gala Sanchez Van MoerDepartment of Bioengineering, University of California San Diego, La Jolla, California, USA.
Daniela LucasDepartment of Bioengineering, University of California San Diego, La Jolla, California, USA.
Pedro CabralesDepartment of Bioengineering, University of California San Diego, La Jolla, California, USA.
Andre F PalmerWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.

Funding

PEGylated megahemoglobin for use as a red blood cell substituteR01HL138116 · NHLBI · OHIO STATE UNIVERSITY · PI CABRALES, PEDRO, KAUMAYA, PRAVIN T. P. · 2017 to 2020
$2.9M
Bioengineering a Dual Function Protein Construct to Detoxify Heme and HemoglobinR01HL159862 · NHLBI · OHIO STATE UNIVERSITY · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2021 to 2024
$2.6M
Bioengineering a novel therapeutic protein complex to minimize the effects of medical device induced hemolysisR01HL162120 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI BUEHLER, PAUL WERNER, CABRALES, PEDRO · 2022 to 2025
$2.6M
Aerosolized therapy for hemoglobin toxicity in the treatment of hemolytic diseasesR01HL158076 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI BUEHLER, PAUL WERNER, IRWIN, DAVID CHARLES · 2022 to 2025
$2.5M
Engineering a novel biomaterial for oxygen transport applicationsR01HL156526 · NHLBI · OHIO STATE UNIVERSITY · PI BUEHLER, PAUL WERNER, PALMER, ANDRE FRANCIS · 2021 to 2024
$2.5M
Training in Bioengineering Research and Technology Development in Cardiovascular in Cardiopulmonary Health and DiseaseT32HL160507 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Karen L Christman, Andrew D. McCulloch · 2022 to 2026
$1.6M
NHLBI NIH HHS R01 HL138116NHLBI NIH HHS R01 HL156526NHLBI NIH HHS R01 HL158076NHLBI NIH HHS R01 HL159862NHLBI NIH HHS R01 HL162120NHLBI NIH HHS T32 HL160507NIH HHS R01HL138116NIH HHS R01HL156526NIH HHS R01HL158076NIH HHS R01HL159862NIH HHS R01HL162120
6 · The paper itself

Abstract

Plasma expanders (PEs) are commonly used to replace lost blood volume for septic shock patients with increased vascular permeability. Human serum albumin (HSA) is the preferred PE, due to its innate ability to restore blood colloid osmotic pressure (COP). However, HSA is susceptible to protein extravasation under endothelial dysfunction leading to edema and exposing tissue to toxic HSA-bound metabolites. To prevent extravasation, the molecular diameter of HSA has been previously increased through chemical polymerization to yield polymerized HSA (PHSA). In this study, we further optimize PHSA size and COP via polyethylene glycol (PEG) surface conjugation. Previously synthesized PHSA that was size fractionated via tangential flow filtration (TFF) into two brackets (bracket A [500 kDa-0.2 μm] and bracket B [50-500 kDa]) served as precursors for subsequent PEGylation. Each PHSA bracket was thiolated with 2-iminothiolane hydrochloride (IT) and PEGylated with monofunctional 5 kDa maleimide PEG to yield PEGylated PHSA (PPHSA). All PPHSA solutions exhibited increased molecular size, zeta potential, and osmolality compared to their non-PEGylated precursor PHSA. At the same total protein concentration, PPHSA viscosity decreased compared to the precursor PHSA, while the COP remained consistent with HSA, indicating their potential to serve as PEs.

Indexed as

Plasma SubstitutesPolyethylene GlycolsSerum AlbuminSerum Albumin, HumanColloidsHumansOsmotic PressurePolymerizationColloidsPlasma SubstitutesPolyethylene GlycolsSerum AlbuminSerum Albumin, Humancolloid osmotic pressureendothelial dysfunctionhuman serum albuminPEGylated polymerized human serum albuminplasma expanderpolymerized human serum albumin

Identifiers

PMID40660704
PMCPMC12696433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.